MC2 Therapeutics

Executive Summary

MC2 Therapeutics is a private, commercial-stage Danish pharmaceutical company specializing in innovative topical therapies for inflammatory skin conditions, with a primary focus on plaque psoriasis. The company's competitive edge lies in its proprietary PAD Technology™, a drug delivery platform designed to enhance the efficacy, skin penetration, and patient experience of topical treatments. MC2's lead product is a prescription cream for psoriasis, which has been commercialized in select markets. The company also offers complementary skincare products, aiming to build a comprehensive portfolio for dermatological conditions. With a strong foundation in drug delivery innovation, MC2 is positioned to capture market share in the topical dermatology space, where patient adherence and formulation elegance are key differentiators.

Upcoming Catalysts (preview)

• Q2 2026Potential partnership or licensing deal for PAD Technology60% success
• Q3 2026Expansion of commercial presence to additional European markets70% success
• Q4 2026Initiation of clinical trial for new indication (e.g., atopic dermatitis)40% success